Sander Strengholt

Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study

J. Wollenhaupt, Eun-Bong Lee, Jeffrey R. Curtis et al. · Arthritis Research & Therapy · 2019 · 320 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +15

Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme

Roy Fleischmann, Jeffrey R. Curtis, Christina Charles‐Schoeman et al. · Annals of the Rheumatic Diseases · 2023 · 53 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +16

Evaluation of the Short‐, Mid‐, and Long‐Term Effects of Tofacitinib on Lymphocytes in Patients With Rheumatoid Arthritis

Ronald van Vollenhoven, Eun Bong Lee, Sander Strengholt et al. · Arthritis & Rheumatology · 2018 · 51 citations · Full text

Life Sciences, Immunology, Pharmacology +17

SAT0234 Tofacitinib, an oral janus kinase inhibitor, in the treatment of rheumatoid arthritis: safety and efficacy in open-label, long-term extension studies over 9 years

J. Wollenhaupt, Joel C. Silverfield, E. B. Lee et al. · Annals of the Rheumatic Diseases · 2018 · 38 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Is radiographic progression in modern rheumatoid arthritis trials still a robust outcome? Experience from tofacitinib clinical trials

Robert Landewé, Carol A. Connell, John Bradley et al. · Arthritis Research & Therapy · 2016 · 31 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +15